Understanding and managing side effects of peptide receptor radionuclide therapy for neuroendocrine tumors
PRRT is generally well-tolerated for neuroendocrine tumors, but clinicians must recognize acute, subacute, and long-term toxicities and identify high-risk patients to optimize safety and outcomes.
Quick Facts
What This Study Found
PRRT toxicities are stratified into acute (nausea, hormone-related crises), subacute (bone marrow suppression, kidney effects), and long-term (renal impairment, myelodysplastic syndrome). Most side effects are transient, but awareness of high-risk factors is essential for prevention and early management.
Key Numbers
Toxicities stratified by onset: acute (during/shortly after), subacute (weeks to months), and long-term (months to years). Reviews kidney toxicity, hematological toxicity, and rare secondary malignancies.
How They Did This
Comprehensive narrative review of toxicity data from PRRT clinical experience, including risk factor identification, management strategies, and recent advances in toxicity prediction and prevention.
Why This Research Matters
As PRRT becomes more widely used for neuroendocrine tumors, clinicians need practical guidance on managing its toxicity profile. Understanding risk factors allows for patient selection optimization and proactive toxicity prevention, maximizing the benefit-to-risk ratio of this peptide-based therapy.
The Bigger Picture
PRRT represents one of the most successful examples of peptide-targeted therapy in oncology. As the field expands to treat more tumor types and develop next-generation radiopeptides, understanding and managing toxicity becomes increasingly critical for safe, widespread clinical adoption.
What This Study Doesn't Tell Us
Narrative review without systematic methodology or meta-analysis of toxicity rates. Toxicity profiles may vary with different radionuclides and peptide ligands. Risk factor evidence comes largely from retrospective analyses.
Questions This Raises
- ?Can predictive biomarkers reliably identify patients at highest risk for PRRT-related kidney or bone marrow toxicity?
- ?How do next-generation radiopeptides (alpha-emitters) compare in toxicity profile to current lutetium-177 PRRT?
- ?Could combination therapies (PRRT + immunotherapy) alter the toxicity landscape?
Trust & Context
- Key Stat:
- Well-tolerated overall Most PRRT side effects are transient, but awareness of kidney, bone marrow, and hormonal toxicities is critical for clinicians managing neuroendocrine tumor patients
- Evidence Grade:
- Narrative review synthesizing clinical experience and published toxicity data. Provides practical clinical guidance but lacks systematic quantification of toxicity rates.
- Study Age:
- Published in 2025; includes recent advances in PRRT toxicity prediction and management.
- Original Title:
- Toxicity manifestations encountered in peptide receptor radionuclide therapy setting.
- Published In:
- Journal of neuroendocrinology, 37(3), e13464 (2025)
- Authors:
- Parghane, Rahul V, Basu, Sandip(2)
- Database ID:
- RPEP-12955
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Frequently Asked Questions
What are the main side effects of PRRT?
The most common side effects include nausea during infusion (acute), temporary drops in blood cell counts (subacute), and potential kidney function decline with repeated treatments (long-term). Most acute side effects resolve on their own. Serious long-term effects like myelodysplastic syndrome are rare but require monitoring.
How safe is PRRT compared to other cancer treatments?
PRRT is generally well-tolerated compared to conventional chemotherapy, with fewer and milder side effects in most patients. It specifically targets tumor cells expressing somatostatin receptors, reducing damage to healthy tissue. However, kidney and bone marrow monitoring is essential throughout treatment.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12955APA
Parghane, Rahul V; Basu, Sandip. (2025). Toxicity manifestations encountered in peptide receptor radionuclide therapy setting.. Journal of neuroendocrinology, 37(3), e13464. https://doi.org/10.1111/jne.13464
MLA
Parghane, Rahul V, et al. "Toxicity manifestations encountered in peptide receptor radionuclide therapy setting.." Journal of neuroendocrinology, 2025. https://doi.org/10.1111/jne.13464
RethinkPeptides
RethinkPeptides Research Database. "Toxicity manifestations encountered in peptide receptor radi..." RPEP-12955. Retrieved from https://rethinkpeptides.com/research/parghane-2025-toxicity-manifestations-encountered-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.